In this section
@article{Periselneris:2019:jac/dkz075,
author = {Periselneris, J and Nwankwo, L and Schelenz, S and Shah, A and Armstrong-James, D},
doi = {jac/dkz075},
journal = {Journal of Antimicrobial Chemotherapy},
pages = {1701--1703},
title = {Posaconazole for the treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.},
url = {http://dx.doi.org/10.1093/jac/dkz075},
volume = {74},
year = {2019}
}
TY - JOUR
AB - OBJECTIVES: Allergic bronchopulmonary aspergillosis (ABPA) can accelerate lung function decline in patients with cystic fibrosis (CF). Antifungal medication can be used in addition to systemic corticosteroid treatment. PATIENTS AND METHODS: We evaluated Aspergillus-specific IgE and the use of therapeutic drug monitoring of triazoles in a retrospective analysis of 32 patients. RESULTS: There was a significant reduction in Aspergillus IgE with posaconazole but not with other triazoles (P=0.026). Aspergillus IgE levels were inversely correlated with the therapeutic drug level of posaconazole. CONCLUSIONS: These data suggest that posaconazole is better than comparator azoles at decreasing serological response to Aspergillus and that this response was better with therapeutic levels of posaconazole.
AU - Periselneris,J
AU - Nwankwo,L
AU - Schelenz,S
AU - Shah,A
AU - Armstrong-James,D
DO - jac/dkz075
EP - 1703
PY - 2019///
SN - 0305-7453
SP - 1701
TI - Posaconazole for the treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.
T2 - Journal of Antimicrobial Chemotherapy
UR - http://dx.doi.org/10.1093/jac/dkz075
UR - https://www.ncbi.nlm.nih.gov/pubmed/30805605
UR - https://academic.oup.com/jac/article/74/6/1701/5364630
UR - http://hdl.handle.net/10044/1/71478
VL - 74
ER -
CBRB
Imperial College London
Flowers Building
Exhibition Road
London SW7 2AZ
